18th May 2022 15:03
Polarean Imaging PLC - London-based medical‑imaging technology - For 2021, annual loss widens to USD14.0 million from USD6.5 million in 2020. Revenue edges upwards to USD1.2 million from USD1.1 million. Selling & distribution expenses surge to USD5.6 million from USD917,783 in 2020.
Sees itself in a "solid financial position" to fund itself "well into 2023." Repeats US Food & Drug Administration has accepted its new drug application resubmission. The FDA set a user fee goal date at late September, it adds. "We continue to identify exciting opportunities in the areas of long Covid, cardiology and pulmonary vascular disease," firm says.
Current stock price: 50.58 pence, up 0.2% on Wednesday
12-month change: down 48%
By Tom Budszus; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
polarean